PCOS has been officially renamed polyendocrine metabolic ovarian syndrome (PMOS). After 14 years, 22,000 voices, and a landmark paper in The Lancet, the world’s most underdiagnosed hormonal condition finally has a name that tells the truth.

For nearly a century, millions of people living with a complex, whole-body hormonal disorder have been handed a diagnosis that described almost nothing about what was actually happening inside their bodies. Polycystic ovary syndrome (PCOS) suggested the problem was cysts, located on the ovaries. The name implied a tidy, anatomical story. The reality is far messier, far more pervasive, and more consequential.

That story changed on May 12, 2026, when The Lancet offi

cially renamed the condition polyendocrine metabolic ovarian syndrome (PMOS). The PCOS name change was simultaneously announced at the European Congress of Endocrinology in Prague, marking the end of a 14-year effort involving 56 organizations, three major global surveys, and over 22,000 patients, clinicians, and advocates from every corner of the world.

“The term polycystic ovary syndrome has long been recognized as inaccurate and potentially harmful.”

The Lancet, May 12, 2026 · Global Consensus Paper

Why PCOS Was Always the wrong name

The word “cystic” in PCOS misled patients and physicians alike for decades. The so-called “cysts” that gave the condition its name are not true cysts in the medical sense. They are actually small, immature follicles: fluid-filled sacs that did not fully develop and release an egg. When surgeons Irving Stein and Michael Leventhal first described enlarged ovaries with these follicles in 1935, the “polycystic” framing stuck. It was always an oversimplification, and one with lasting consequences for PCOS diagnosis and treatment.

The result? Generations of patients and their doctors were oriented toward the ovaries, when the true drivers of PMOS lie upstream: in the endocrine system, in insulin resistance, in neuroendocrine signaling and metabolic function. The ovaries are, in many ways, are where the consequences show up.

The old PCOS name also obscured the condition’s extraordinary breadth. PMOS does not just affect reproductive health. It has documented links to type 2 diabetes, cardiovascular disease, mental health disorders, thyroid dysfunction, sleep apnoea, and more. Framing it as a syndrome “of the ovaries” led to fragmented care: gynecologists treated the fertility symptoms, but the metabolic and psychological dimensions of the condition often went unaddressed.

How Many People Does PMOS Affect?

PMOS (formerly PCOS) is the most common hormonal disorder affecting people with ovaries worldwide. It impacts roughly 170 million people, or 1 in 8 women of reproductive age. To put that in context: PMOS is more prevalent than breast cancer and type 1 diabetes combined, yet it remains dramatically underfunded and under-researched relative to its scale.

Perhaps the most alarming PMOS statistic: an estimated 70% of cases remain undiagnosed globally. Many people go years, sometimes decades, cycling through appointments, dismissals, and misdiagnoses before receiving a correct one. Researchers and advocates have argued that the misleading PCOS name contributed directly to this diagnostic failure, both by confusing clinicians who do not specialize in it and by causing patients to question whether their symptoms could possibly share a single cause.

The condition disproportionately burden

s those already marginalized in healthcare systems. Studies show that women of color, women with higher body weights, and women in lower-income countries experience even longer diagnostic delays. The stigma embedded in a name associated with “cysts” and fertility problems has made open conversation harder for everyone living with PMOS symptoms.

The Timeline: 14 Years to Rename a Condition

What Does the PCOS to PMOS Name Change Actually Mean?

The condition itself has not changed. Every symptom, every complication, every treatment pathway that existed under the name PCOS still applies to PMOS. What changes is the framing, and framing, in medicine, is everything.

The new name does significant work. “Polyendocrine” signals that multiple hormonal systems are involved in PMOS. This is not simply a reproductive disorder. “Metabolic” directs clinicians toward insulin resistance, glucose regulation, and cardiovascular risk as central concerns. “Ovarian” is retained to acknowledge the role the ovaries play in symptom expression, while “syndrome” reflects the multi-system, complex nature of the condition.

The rollout is deliberately gradual. Over the next three years, clinical guidelines covering PMOS will be updated in 195 countries, medical education curricula will be revised, and international disease classification systems will adopt the new terminology. The transition acknowledges that healthcare systems move slowly and that change at scale requires infrastructure, not just a declaration.

“By putting ‘endocrine’ and ‘metabolic’ in the name, PMOS tells clinicians this is a whole-body condition — not just a problem to refer to a gynecologist.”

Dr. Sherry Ross, OB-GYN and Women’s Health Expert

Why Did It Take So Long to Rename PCOS?

Researchers working on the PCOS to PMOS rename have pointed to a systemic underinvestment in women’s hormonal health. PMOS research has received a fraction of the funding that comparable conditions affecting men have attracted, even at the same prevalence levels.

The PMOS name change is expected to have cascading effects. Clearer terminology may open new research funding streams from endocrinology, cardiology, and metabolic medicine departments that previously saw PCOS as someone else’s problem. It may prompt more multi-disciplinary care models. And perhaps most importantly, it may help the millions of people currently living undiagnosed recognize their PMOS symptoms for what they are.

There is also acknowledged tension in the new name. Some researchers have noted that retaining “ovarian” may exclude the possibility, suggested by emerging early research, that a form of this condition exists in people without ovaries. The consortium has not ruled out future revisions as the science evolves.

PMOS: A New Name, A New Conversation

For the millions of people who have spent years being told that their exhaustion, weight fluctuations, mood disorders, skin issues, and irregular cycles were separate and unrelated problems, or worse, personal failings, the renaming of PCOS to PMOS is more than semantic. It is a validation that PMOS is a real, complex, systemic, and serious condition that deserves proper recognition and care.

PMOS (polyendocrine metabolic ovarian syndrome) finally gives this condition the name it always deserved: one that accurately reflects what it is and what it does to the body.